Followers | 29 |
Posts | 6046 |
Boards Moderated | 1 |
Alias Born | 04/28/2013 |

Wednesday, February 22, 2023 10:26:19 PM
Many bagholders waiting hopelessly at this time
Recent OCGN News
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 02/21/2025 01:00:45 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2025 05:15:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2025 01:39:20 PM
- Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 02/12/2025 12:42:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/07/2025 09:06:13 PM
- Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa • GlobeNewswire Inc. • 02/03/2025 11:30:42 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/31/2025 09:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2025 02:04:19 PM
- Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 • GlobeNewswire Inc. • 01/27/2025 11:30:20 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema • GlobeNewswire Inc. • 01/16/2025 12:30:38 PM
- Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa • GlobeNewswire Inc. • 01/13/2025 11:30:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:02:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:02:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:01:03 PM
- Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 12/19/2024 11:38:37 AM
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit • GlobeNewswire Inc. • 12/11/2024 12:02:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 02:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2024 09:15:25 PM
- Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference • GlobeNewswire Inc. • 11/27/2024 12:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:50:10 PM
- Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease • GlobeNewswire Inc. • 11/20/2024 12:30:00 PM
- Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 11/19/2024 12:02:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2024 09:17:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 09:05:24 PM
FEATURED ImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada • Feb 25, 2025 8:00 AM
Consumer Automotive Finance, Inc. Finalizes Agreement to Retire 246 Million Common Shares: Strategic Move Signals Robust Commitment to Shareholder Value Enhancement • CAFI • Feb 25, 2025 9:00 AM
VAYK To Offer Service Solution Capitalizing on $11.1 Billion Airbnb Revenue • VAYK • Feb 24, 2025 9:00 AM
ConnectM Announces $11.3M Q1 '25 Preliminary Revenue Guidance, a 100% YoY Surge • CNTM • Feb 24, 2025 9:00 AM
ConnectM Announces Q1 2025 Preliminary Revenue Guidance of $11.3M, Representing a 100% Year-Over-Year Surge • CNTM • Feb 21, 2025 7:17 AM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM